QUOTED. 26 July 2019. Michael Mahoney.
Boston Scientific beat Wall Street's second-quarter profit expectations, but fell shy of analysts' predictions on revenue. See what Boston Scientific's CEO Michael Mahoney said about it here.
“The combined strength of Watchman, Acurate, Lotus Edge and Sentinel position us well to deliver on our guidance for $700m to $725m in structural heart revenue in 2019.” – Michael Mahoney, CEO, Boston Scientific
Click here for a free trial of Medtech Insight